SOURCE: Cryobanks

March 02, 2006 10:30 ET

Cryobanks International Recognizes The University of Minnesota for Recent Stem Cell Discovery

ALTAMONTE SPRINGS, FL -- (MARKET WIRE) -- March 2, 2006 --Research published in the latest issue of the journal, "Stem Cells and Development," reveals new findings that identify a small population of cord blood cells with characteristics of more primitive cells. These primitive stem cells have the potential to produce a greater variety of cell types than was previously shown to be obtainable from umbilical cord blood (cord blood) at birth.

To date, cord blood has been thought of as being blood cell producing, ie: white cells, red cells, and platelets. "This new discovery gives an indication as to what we have always suspected; that cord blood stem cells can differentiate to become all types of cells in the body," said Dwight Brunoehler, President & CEO of Cryobanks International (OTC BB: BTEM).

According to a study conducted at The Stem Cell Institute at The University of Minnesota, human cord blood stem cells were transplanted into laboratory rodents with strokes resulting in significant reductions in the size of brain lesions while improving the animal's use of their limbs. Some of the transplanted cells developed into neuron-like cells that are typically found in the brain. Furthermore, the transplanted cells also induced a reorganization of host nerve fibers possibly explaining why the rats regained function.

"Findings like the one at The University of Minnesota continue to pave the way for use of non controversial cord blood stem cells for treating neurological disorders in humans," according to Mr. Brunoehler. Stroke is a neurological disorders that affects approximately 750,000 people in the United States each year.

About Cryobanks:

Cryobanks International, is located in Altamonte Springs, FL. The Company is a leader in the collection, processing, and banking of stem cells derived from the umbilical cord immediately after birth. The units of cord blood are processed and stored by the company for use in unrelated transplants (where the donor is a histocompatible match, but is anonymous and unrelated to the recipient) and for personal storage and use. In recent years, cord blood transplants (CBTs) have become widely recognized as a safe, effective, and in many ways preferable, alternative to bone marrow transplant. There is tremendous potential need for CBTs in the United States and worldwide. Cryobanks International is well poised to help meet that need, equipped with an inventory of over 8,500 cord blood units. For more information about Cryobanks International call 1-800-869-8608 or visit the website at www.cryo-intl.com.

Contact Information